EA Pharma
Manufacturing · Japan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Central District, Tokyo, 1040042, JapanPhone Number
+81 8041765206Website
www.eapharma.co.jpRevenue
$7.4 MillionIndustry
About EA Pharma
EA Pharma Org Chart
Is EA Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if EA Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when EA Pharma launches new products
Check out if EA Pharma is spiking on competitors!
Earning: See what the market has to say on EA Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at EA Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once EA Pharma has new funding data
EA Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if EA Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined EA Pharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
EA Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EA Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EA Pharma.
EA Pharma Tech Stack
A closer look at the technologies used by EA Pharma
EA Pharma News & Media
Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho Therapeutics
Ensho Acquired Rights to Develop and Commercialize EA1080 and Portfolio of Other Oral Selective α4β7 Integrin Antagonists in All Territories Excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEAN Ensho Acquired Rights to Develop and Commercialize EA1080 and Portfolio of Other Oral Selective α4β7 Integrin Antagonists in All Territories Excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEANPathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease
RESEARCH TRIANGLE PARK, N.C., March 1, 2022 /PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class therapies for patients with chronic kidney disease (CKD), today announced its formation...Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
TOKYO, Sep 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA"). This approval allows for 40 mg weekly treatment or 80 mg biweekly treatment in addition to conventional 40 mg biweekly treatmentAbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
TOKYO, Sep 13, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering Service for Patients" an initiative intended to improve patients' adherence to Humira therapy. "Humira Support Tool Ordering Service for Patients" is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location. Patients
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EA Pharma
EA Pharma Co Ltd is a company that operates in the Pharmaceuticals industry. It employs 50to99 people and has 5Mto10M of revenue. The company is headquartered in Central District, Tokyo, Japan.... Read More